Novo Nordisk A/S
Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S & […]
Read More
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said […]
Read More
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. The initial study […]
Read More
Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. Victoria Klesty | Reuters Novo Nordisk‘s parent company on Monday said it will acquire drug manufacturer Catalent in a $16.5 billion deal that could help boost the supply of the highly popular weight loss injection […]
Read More
Want to cash in on the fat-reduction drug increase? Morgan Stanley names 4 global shares
Drug makers these kinds of as Eli Lilly and Novo Nordisk have been very hot favorites among the traders in the previous 12 months, specified the favourable reception to their pounds-decline medications. “The uptake of GLP-1 (glucagon-like-pepitide-1) course AOMs (anti-weight problems drugs) has been unexpectedly robust, specially in the U.S. the place the medicines are […]
Read More
Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars
Liselotte Sabroe | Afp | Getty Pictures Novo Nordisk, Europe’s premier firm by market capitalization, on Wednesday noted improved-than-expected 2023 earnings, as sales of its wildly common anti-weight problems and diabetic issues prescription drugs ongoing to soar. The maker of excess weight decline drug Wegovy and diabetic issues drug Ozempic reported an enhance in gross […]
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People’s Action, protesting pharmaceutical companies’ lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021. Saul Loeb | AFP | Getty Images The CEOs of Merck and […]
Read More
LVMH shares soar around 12% as earnings position to luxurious sector resilience
Bernard Arnault, Chairman and CEO of LVMH Moet Hennessy Louis Vuitton, speaks for the duration of a push meeting to existing the 2023 yearly effects of LVMH in Paris, France, January 25, 2024. Benoit Tessier | Reuters LVMH shares jumped additional than 12% on Friday early morning, immediately after the world’s greatest luxurious group posted […]
Read More
Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved […]
Read More
Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
The anti-obesity drug market is expected to remain in focus this year after a bumper 2023 for weight loss drugmakers Novo Nordisk and Eli Lilly , according to Berenberg. The Germany-headquartered investment bank expects a combination of new clinical data, and the expiry of Novo ‘s patent for the active ingredient in first-generation GLP-1 drugs, […]
Read More